PMID- 19232095
OWN - NLM
STAT- MEDLINE
DCOM- 20091207
LR  - 20211020
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 8
DP  - 2009 Feb 20
TI  - Myeloid-related protein 8/14 complex describes microcirculatory alterations in 
      patients with type 2 diabetes and nephropathy.
PG  - 10
LID - 10.1186/1475-2840-8-10 [doi]
AB  - BACKGROUND: Inflammation contributes to cardiovascular complications in type 2 
      diabetes, which are often characterized by microvascular alterations. We 
      investigated whether myeloid-related protein 8/14 complex (MRP8/14) secreted by 
      transmigrating monocytes and granulocytes may represent a biomarker for 
      microvascular alterations in patients with type 2 diabetes and nephropathy. 
      METHODS: MRP8/14 was measured in 43 patients with type 2 diabetes and 
      nephropathy. Additionally, the inflammatory markers Interleukin-6 (IL-6), Tumor 
      necrosis factor-alpha (TNF-alpha) and C-reactive protein (CRP) were quantified. 
      To detect microvascular alterations proteinuria and retinal vessel caliber were 
      used as classical and novel marker, respectively. Proteinuria was quantified by 
      protein-creatinine ratio (PCR); retinal vessel caliber was quantified after 
      retina photography on digitalized retina pictures. RESULTS: MRP8/14 was 
      positively associated with inflammation (r = 0.57), proteinuria (r = 0.40) and 
      retinal arterial caliber (r = 0.48). Type 2 diabetic patients with MRP8/14 values 
      above the median of 5.8 microg/ml demonstrated higher proteinuria and larger 
      retinal artery caliber than patients with MRP8/14 values below the median 
      (logPCR: -0.51 +/- 0.52 versus -0.96 +/- 0.46, P < 0.01; retinal artery lumen 
      (microm): 178.3 +/- 14.1 versus 162.7 +/- 14.9 P < 0.01). Both groups did not 
      differ with regard to metabolic factors and blood pressure. MRP8/14 was an 
      independent predictor of retinal artery caliber in multivariate stepwise 
      regression analysis (beta = 0.607) and was positively associated with IL-6 (r = 
      0.57, P < 0.001) and TNF-alpha (r = 0.36, P < 0.05). CONCLUSION: MRP8/14--a 
      marker for transendothelial migration--describes not only the state of 
      inflammation in diabetic nephropathy, but additionally the degree of 
      microvascular alterations in the glomerular and retinal bed. Therefore, MRP8/14 
      may be a potentially selective novel biomarker for microcirculatory defects in 
      diabetic nephropathy.
FAU - Burkhardt, Klaus
AU  - Burkhardt K
AD  - Nephrological Clinic Weissenburg, 91781 Weissenburg, Germany. 
      praxis-dr-burkhardt@t-online.de
FAU - Schwarz, Sonja
AU  - Schwarz S
FAU - Pan, Chengrui
AU  - Pan C
FAU - Stelter, Felix
AU  - Stelter F
FAU - Kotliar, Konstantin
AU  - Kotliar K
FAU - Von Eynatten, Maxilian
AU  - Von Eynatten M
FAU - Sollinger, Daniel
AU  - Sollinger D
FAU - Lanzl, Ines
AU  - Lanzl I
FAU - Heemann, Uwe
AU  - Heemann U
FAU - Baumann, Marcus
AU  - Baumann M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20090220
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
RN  - 0 (ABCC11 protein, human)
RN  - 0 (ATP-Binding Cassette Transporters)
RN  - 0 (Biomarkers)
RN  - 0 (Calgranulin B)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - ATP-Binding Cassette Transporters/*blood
MH  - Aged
MH  - Biomarkers/blood
MH  - Calgranulin B/*blood
MH  - Cohort Studies
MH  - Diabetes Mellitus, Type 2/*blood/drug therapy/physiopathology
MH  - Diabetic Nephropathies/*blood/drug therapy/physiopathology
MH  - Etanercept
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/therapeutic use
MH  - Male
MH  - Microcirculation/*physiology
MH  - Middle Aged
MH  - Receptors, Tumor Necrosis Factor/therapeutic use
MH  - Retinal Vessels/physiopathology
PMC - PMC2654885
EDAT- 2009/02/24 09:00
MHDA- 2009/12/16 06:00
PMCR- 2009/02/20
CRDT- 2009/02/24 09:00
PHST- 2008/12/17 00:00 [received]
PHST- 2009/02/20 00:00 [accepted]
PHST- 2009/02/24 09:00 [entrez]
PHST- 2009/02/24 09:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
PHST- 2009/02/20 00:00 [pmc-release]
AID - 1475-2840-8-10 [pii]
AID - 10.1186/1475-2840-8-10 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2009 Feb 20;8:10. doi: 10.1186/1475-2840-8-10.